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z 	Evidence summary
A 2006 meta-analysis, including 114 tri-
als and 116,094 patients randomized to 
either cyclooxygenase-2 (COX-2) inhibi-
tor or control (placebo, nonsteroidal anti-
inflammatory drug [NSAID], or mixed), 
indicated that the COX-2 inhibitors, as a 
class, had no effect on renal endpoints.3 
Trials were reviewed for data on renal 
endpoints, including peripheral edema, 
hypertension, and renal dysfunction (de-
fined as significant worsening of serum 
urea or creatinine, or clinical evidence of 
kidney disease and renal failure). 
When viewed separately, rofecoxib 
(Vioxx) was associated with a compos-
ite relative risk (RR) of 1.53 (95% con-
fidence interval [CI], 1.33–1.76) for all 
renal endpoints compared with controls. 
In contrast, the composite RR for the 
same endpoints among patients taking 
celecoxib (Celebrex) was 0.97 (95% CI, 
0.84–1.12), indicating no effect on renal 
function. In fact, for the specific outcomes 
of hypertension and renal dysfunction, ce-
lecoxib was associated with a decreased 
risk compared with controls (TablE).3
Stratified analysis by type of control 
(placebo, alternate NSAID, or mixed) 
yielded consistent results; rofecoxib was 
uniquely associated with adverse renal 
outcomes. No effect on renal function 
was noted for celecoxib compared with 
the same controls: the RR for adverse 
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Do COX-2 inhibitors  
worsen renal function?
Use celecoxib cautiously in patients 
at risk of serious complications 
recent	studies	have	raised	concerns	about	
the	safety	of	this	class	of	medication.	
For	example,	rofecoxib	was	linked	with	
increased	cardiovascular	events,	leading	to	
it	being	pulled	from	the	market.1	The	claim	
of	decreased	gastrointestinal	bleeding	with	
long-term	use	of	CoX-2	inhibitors	has	also	
been	questioned.2	
	 Although	this	Clinical	Inquiry	concludes	
that	celecoxib	does	not	appear	to	worsen	
renal	function,	it	should	still	be	used	
with	caution	for	patients	who	are	elderly,	
hospitalized,	or	at	risk	of	developing	serious	
complications	such	as	acute	renal	failure,	
heart	failure,	and	gastrointestinal	bleeding.	
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Clinical commentary
Evidence-based answer
No,	CoX-2	inhibitors,	as	a	class,	do	not	
worsen	renal	function	for	those	without	renal	
disease.	Celecoxib	is	the	only	CoX-2	inhibi-
tor	available,	and	it	is	associated	with	a	low-
er	risk	of	renal	dysfunction	and	hypertension	
when	compared	with	controls.	Available	data	
do	not	allow	for	adjusted	risk	assessment	
for	patients	with	preexisting	renal	disease	on	
CoX-2	inhibitors	(strength	of	recommenda-
tion	[sor]:	A,	based	on	meta-analysis).
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renal effects was 0.87 (95% CI, 0.55–
1.38), 0.93 (95% CI, 0.70–1.23), and 
1.26 (95% CI, 0.94–1.69) for celecoxib 
vs placebo, NSAID, and mixed controls, 
respectively. Statistical analysis for het-
erogeneity showed that the variation 
in effects on renal function among the 
COX-2 inhibitors was more likely due 
to actual differences than due to chance 
(heterogeneity [I2]=57%; P<.001).
Data were not available to assess 
the effect of COX-2 agents on patients 
with pre-existing renal disease, primarily 
because trials reporting abnormal renal 
function at baseline were excluded from 
this meta-analysis. 
A recent randomized controlled trial 
compared standard dosing of diclofenac 
(75 mg twice daily) and ibuprofen (800 
mg 3 times daily) with high-dose celecox-
ib (400 mg twice daily) for patients with 
normal kidney function being treated for 
osteoarthritis and rheumatoid arthritis.4 
The mean increase in serum creatinine 
in the celecoxib arm was less than that 
noted in the diclofenac controls (0.009 
mg/dL vs 0.027 mg/dL; P<.05; number 
needed to harm [NNH]=56). No differ-
ence in mean serum creatinine was seen 
among those patients using ibuprofen 
(800 mg 3 times daily) compared with 
those using high-dose celecoxib. 
This evidence further supports the 
safety of celecoxib vs standard NSAIDs 
with respect to renal dysfunction.
Recommendations from others
The American Pain Society 2002 guideline 
recommends acetaminophen for mild 
pain from osteoarthritis.5 For moderate 
to severe pain and inflammation, a COX-
2 inhibitor was the first choice, unless 
there is significant risk of hypertension or 
kidney disorder. For active rheumatoid ar-
thritis, the addition of a COX-2 agent to 
disease-modifying anti-rheumatic drugs 
(DMARDs) is advised unless there is un-
controlled hypertension or renal disease.6 
However, these recommendations came 
out before the data on the cardiovascular 
effects of some COX-2 inhibitors.
The American College of rheumatolo-
gy recommends the use of a COX-2 agent 
for osteoarthritis or pain unresponsive to 
acetaminophen. Their 2000 guidelines 
warn that due to potential renal toxicity, 
COX-2 inhibitors should not be used for 
patients with severe renal insufficiency, 
and used with caution in cases of mild to 
moderate renal insufficiency. 
In 2005, these guidelines were amend-
ed to include the recommendation that 
patients with increased cardiovascular 
risk be cautioned about the risks associ-
ated with COX-2 inhibitor use.7   n
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Celecoxib is associated with a decreased risk 
of hypertension and renal dysfunction
 CElECoxib rofECoxib
hypertension	 0.83	(95%	CI,	0.71–0.97)	 1.55	(95%	CI,	1.29–1.85)
Peripheral edema	 1.09	(95%	CI,	0.91–1.31)	 1.43	(95%	CI,	1.23–1.66)
renal dysfunction	 0.61	(95%	CI,	0.40–0.94)	 2.31	(95%	CI,	1.05–5.07)
Source: Zhang	J,	Ding	el,	song	Y,	JAMA 2006.3
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